Drug intelligence / Profile preview

BSEM-125

Development stage: Preclinical
Lead developer: Nesvik Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

BSEM-125 is a reformulated pharmaceutical product developed by Nesvik Pharmaceuticals, a subsidiary of BioStem Technologies, as a liquid delivery formulation of a **calcium channel inhibitor** intended for the treatment of **hypertension**. It targets patients unable to take tablets or capsules, pursuing FDA approval via the 505(b)(2) pathway by leveraging existing data on the reference drug to expedite market entry. The project originated from an asset acquisition involving multiple reformulated compounds.[1][3][5][7]

Targets

CaV (Voltage-gated calcium channel protein complex)

Beyond the preview

Go deeper on BSEM-125.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BSEM-125.

Explore the full profile